Arcturus Therapeutics is trading at $10.48, down 5.33%, amid broader risk-off sentiment; no clear company-specific catalyst was identified for the October 22 decline. - Geopolitical tensions are pushing oil higher as investors reassess AI spending; the Nasdaq was down more than 0.5%. - ARCT-810 interim results and the LUNAR 2.0 announcement were dated September 23, not new October 22 developments. - Trading volume information is unavailable in the provided price context.